ARN-509: a novel anti-androgen for prostate cancer treatment

Continued reliance on the androgen receptor (AR) is now understood as a core mechanism in castration-resistant prostate cancer (CRPC), the most advanced form of this disease. While established and novel AR-pathway targeting agents display clinical efficacy in metastatic CRPC, dose-limiting side effe...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Clegg, Nicola J., Wongvipat, John, Joseph, Jim, Tran, Chris, Ouk, Samedy, Dilhas, Anna, Chen, Yu, Grillot, Kate, Bischoff, Eric D., Cai, Ling, Aparicio, Anna, Dorow, Steven, Arora, Vivek, Shao, Gang, Qian, Jing, Zhao, Hong, Yang, Guangbin, Cao, Chunyan, Sensintaffar, John, Wasielewska, Teresa, Herbert, Mark R., Bonnefous, Celine, Darimont, Beatrice, Scher, Howard I., Smith-Jones, Peter, Klang, Mark, Smith, Nicholas D., De Stanchina, Elisa, Wu, Nian, Ouerfelli, Ouathek, Rix, Peter J., Heyman, Richard A., Jung, Michael E., Sawyers, Charles L., Hager, Jeffrey H.
التنسيق: Artigo
اللغة:Inglês
منشور في: 2012
الموضوعات:
Article
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC3306502/
https://ncbi.nlm.nih.gov/pubmed/22266222
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-11-3948
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة